Daily Respiratory Research Analysis
Analyzed 221 papers and selected 3 impactful papers.
Summary
Long-term oncologic outcomes from KEYNOTE-042 (China) confirm durable overall survival benefit and better tolerability for first-line pembrolizumab in PD-L1-positive advanced NSCLC. A cross-sectional bronchoalveolar study demonstrates potent lower-airway neutralizing antibodies after BNT162b2 vaccination, with higher specific activity of mucosal IgG than serum but reduced activity against Omicron. A phase 2 trial (IFCT-1802) shows first-line durvalumab is safe and yields clinically meaningful survival in NSCLC patients with poor performance status (ECOG 2–3) and high PD-L1.
Research Themes
- Immunotherapy for lung cancer: long-term efficacy and safety
- Mucosal immunity in the lower respiratory tract after mRNA vaccination
- Treatment strategies for NSCLC patients with poor performance status
Selected Articles
1. Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.
In a 5-year follow-up of Chinese participants in KEYNOTE-042, pembrolizumab sustained overall survival benefits over platinum-based chemotherapy across PD-L1 TPS thresholds (≥1/≥20/≥50%) with markedly fewer grade 3–5 adverse events. These data reinforce pembrolizumab monotherapy as a standard first-line option for PD-L1–positive advanced NSCLC without EGFR/ALK alterations.
Impact: Long-term randomized data confirming survival advantage and improved tolerability directly influence first-line treatment decisions in PD-L1–positive NSCLC.
Clinical Implications: Pembrolizumab monotherapy remains a preferred first-line therapy across PD-L1 TPS ≥1% thresholds in Chinese patients, with durable OS benefits and fewer severe adverse events compared with chemotherapy.
Key Findings
- Pembrolizumab improved OS vs chemotherapy at PD-L1 TPS ≥50% (HR 0.65), ≥20% (HR 0.67), and ≥1% (HR 0.66).
- Grade 3–5 treatment-related adverse events were 19.5% with pembrolizumab vs 68.8% with chemotherapy.
- Median follow-up was 63.7 months in 262 participants, confirming durability of benefit.
Methodological Strengths
- Randomized phase 3 trial with long-term (median 63.7 months) follow-up
- Predefined PD-L1 TPS subgroup analyses across multiple thresholds
Limitations
- Geographically restricted to China; generalizability outside the setting may vary
- Open-label design and potential post-progression treatment imbalances
Future Directions: Evaluate biomarker combinations beyond PD-L1, real-world effectiveness across broader ethnic populations, and optimal sequencing with chemo-immunotherapy.
In the phase 3 KEYNOTE-042 China study of participants enrolled in China in the global KEYNOTE-042 (NCT02220894) and China extension (NCT03850444) studies, pembrolizumab improved overall survival (OS) versus chemotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% (hazard ratio [HR], 0.63; 95% CI, 0.43-0.94), ≥20% (0.66; 0.47-0.92), and ≥1% (0.67; 0.50-0.89). We present outcomes from this study after 5 years of follow-up. Chinese participants with previously untreated locally advanced or metastatic NSCLC with PD-L1 TPS ≥1% without EGFR or ALK alterations were eligible. Participants were randomized 1:1 to pembrolizumab 200 mg every 3 weeks for up to 35 cycles or carboplatin plus paclitaxel or pemetrexed with optional pemetrexed maintenance (nonsquamous only). Primary endpoints were OS in the PD-L1 TPS ≥50%, ≥20%, and ≥1% subgroups. Median follow-up was 63.7 (range, 56.3-72.6) months among 262 participants (pembrolizumab, n = 128; chemotherapy, n = 134) included in this study. Pembrolizumab prolonged OS versus chemotherapy in participants with PD-L1 TPS ≥50% (HR, 0.65; 95% CI, 0.45-0.93), ≥20% (0.67; 0.49-0.91), and ≥1% (0.66; 0.51-0.87). Grade 3 to 5 treatment-related AEs occurred in 19.5% and 68.8% of participants in the pembrolizumab and chemotherapy groups, respectively. In conclusion, after 5 years of follow-up, pembrolizumab continued to demonstrate improved OS versus chemotherapy with manageable safety in Chinese participants with previously untreated locally advanced or metastatic NSCLC that expressed PD-L1. These data further support pembrolizumab monotherapy as a standard of care for these patients.
2. Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.
In poor-PS (ECOG 2–3), PD-L1–high stage IV NSCLC, first-line durvalumab had acceptable early safety (10% grade ≥3 TRAEs in 8 weeks; no grade 5) and yielded an ORR of 26%, median OS of 7.1 months, and a 12-month OS rate of 40%. Outcomes were notably better in PS 2 than PS 3, and nearly half of evaluable patients had improved PS by week 8.
Impact: Addresses a major evidence gap by prospectively evaluating immunotherapy in patients typically excluded from trials (ECOG PS 2–3), informing real-world treatment decisions.
Clinical Implications: Durvalumab monotherapy is a reasonable first-line option for PD-L1–high NSCLC patients with PS 2, with careful selection and monitoring; benefit in PS 3 appears limited and requires individualized risk–benefit assessment.
Key Findings
- Grade ≥3 TRAEs in the first 8 weeks occurred in 10% with no grade 5 events.
- Blinded independent central review ORR at 8 weeks was 26%; median OS 7.1 months, 12-month OS rate 40%.
- Median OS differed by PS: 11.4 months (PS 2) vs 3.0 months (PS 3); 44.4% improved PS at week 8 among evaluable patients.
Methodological Strengths
- Prospective multicenter phase II design in a high-need, understudied population
- Blinded independent central review of tumor responses
Limitations
- Single-arm design without a control group limits comparative efficacy interpretation
- Modest sample size (n=50) and heterogeneity within PS 2–3 subgroup
Future Directions: Randomized comparisons versus best supportive care or chemo-immunotherapy in PS 2; biomarker refinement beyond PD-L1 to identify responders among PS 3.
INTRODUCTION: Eastern Cooperative Oncology Group performance status 2 to 3 is associated with poor survival and chemotherapy-related adverse events. The impact of poor PS on the safety and efficacy of immune checkpoint inhibitors has not been elucidated. This study aimed to assess first-line durvalumab in patients with PS 2 to 3 with advanced NSCLC and high programmed cell death-ligand 1 (PD-L1) expression. METHODS: In this single-arm, prospective, multicenter, phase II trial, patients with PS 2 to 3 aged 18 to 75 years with metastatic NSCLC and PD-L1 tumor proportion score more than or equal to 25% received durvalumab until progression or toxicity. Primary end point was safety, that is incidence of grade more than or equal to 3 TRAEs during the first 8 weeks. Secondary end points included blinded independent central review overall response rate, progression-free survival, duration of response, overall survival (OS), and PS improvement at 8 weeks and health-related quality of life. RESULTS: A total of 50 patients were enrolled. Median follow-up was 26.2 (19.9-35.2) months. Prevalence of grade more than or equal to 3 TRAEs during the first 8 weeks was 10.0% (five of 50, 95% confidence interval [CI] 1.7-18.3), and no grade 5 occurred. Overall response rate at 8 weeks was 26% (95% CI 13.8-38.2). Median duration of response, progression-free survival, and OS were 11.8 months (95% CI, 7.2-not reached), 2.3 months (95% CI 1.7-5.6), and 7.1 months (95% CI 3.9-14.5), respectively. The 12-month OS rate was 40% (95% CI 26.5-53.1). Median OS in patients with PS 2 and PS 3 was 11.4 (95% CI 4.4-32.8) and 3.0 (95% CI 0.2-5.6) months, respectively. Of 27 patients, 12 (44.4%) still receiving durvalumab at 8 weeks had improved PS ( CONCLUSIONS: In patients with a PS of 2 to 3 with advanced NSCLC and high PD-L1 expression, first-line durvalumab was safe with 40% 1-year OS.
3. BNT162b2 vaccine induces potent SARS-CoV-2 neutralising immunoglobulins in lung mucosa.
Among 100 individuals, BNT162b2 elicited detectable anti-RBD antibodies in BALF, with highest IgG/IgA concentrations in four-dose vaccinees. BALF neutralization was strong for ancestral/Delta variants but reduced for Omicron; mucosal IgG correlated with serum IgG and showed ~5.5-fold higher specific neutralizing activity than serum IgG.
Impact: Reveals robust lower-airway mucosal neutralization after vaccination and quantifies superior specific activity of mucosal IgG, informing strategies for booster design and mucosal vaccine development.
Clinical Implications: Supports the protective role of lower-airway mucosal antibodies after vaccination and highlights limitations against Omicron; underscores the potential value of boosting mucosal immunity.
Key Findings
- Anti-RBD IgG and IgA were detectable in BALF, highest in four-dose vaccinees (median IgG 0.59 nM; IgA 0.06 nM).
- BALF neutralization was strong for wild-type/Delta but substantially lower for Omicron.
- BALF and serum IgG levels correlated (r=0.51), and BALF IgG had ~5.5-fold higher specific neutralizing activity than serum IgG.
Methodological Strengths
- Direct assessment of lower-airway mucosal immunity via BALF in 100 bronchoscoped individuals
- Concurrent measurement across compartments (serum, saliva, BALF) with functional neutralization assays
Limitations
- Cross-sectional design precludes longitudinal durability assessment
- Clinical bronchoscopy cohort may not represent general population
Future Directions: Longitudinal tracking of mucosal immunity, evaluation of intranasal or mucosal boosters, and correlates of protection in breakthrough infection.
INTRODUCTION: Functional aspects of pulmonary immunity to SARS-CoV-2 infection and BNT162b2 mRNA vaccination in humans and their correlation with upper airway and systemic immunity remain largely unexplored. The aim of the present study was to explore anti-SARS-CoV-2 immunoglobulin levels and neutralisation in the lower airway mucosa and correlate them with salivary and systemic responses among BNT162b2 recipients. METHODS: Serum, saliva and bronchoalveolar lavage fluids (BALF) were collected from 100 individuals undergoing clinically indicated bronchoscopy. Anti-receptor binding domain (RBD) antibody levels and functional neutralisation were assessed. RESULTS: Anti-RBD antibodies were present in BALF of vaccinees and recovered individuals. IgGs and IgAs were highest among four-dose vaccinees (median 0.59 nM (IgG), 0.06 nM (IgA)). Neutralisation demonstrated augmented lower-airway mucosa protection against wild-type and Delta variant, while BALF neutralisation towards Omicron was substantially lower. While IgG levels among vaccinees correlated between BALF and serum (r=0.51, p=0.001), and between saliva and serum (r=0.58, p=0.001), the IgA levels between fluids did not correlate significantly. The correlation between BALF and serum antibodies was stronger in individuals who experienced previous SARS-CoV-2 infection. Comparison of specific neutralising activity of BALF and serum anti-SARS-CoV-2 IgGs suggested a 5.5-fold increased potency of the former. CONCLUSION: The BNT162b2 vaccine elicits neutralising antibodies against the ancestral variants in the lower respiratory tract. The anti-RBD IgG response correlates overall between systemic and local mucosal sites, while the IgA distributions between BALF, saliva and serum seen specifically following natural exposure suggest locally specialised mucosal immunity. The higher neutralising potency of mucosal IgGs compared to circulatory IgGs highlights the protective importance of mucosal-specific IgGs in the alveolar space.